Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

This study is testing a combination of targeted drugs — including rituximab, inotuzumab ozogamicin, and blinatumomab — as a chemotherapy-light regimen (called Pedi-cRIB) for children, teenagers, and young adults with relapsed or treatment-resistant B-cell acute lymphocytic leukemia (B-ALL) who cannot tolerate certain standard chemotherapy agents. **You may be eligible if...** - You are a child, adolescent, or young adult with B-cell ALL that has relapsed or not responded to initial treatment - Your leukemia cells express CD19 and CD22 proteins (confirmed by lab testing) - You are unable to receive anthracycline chemotherapy OR have an intolerance to PEG-asparaginase - Your general health is adequate (Lansky ≥ 50 for patients under 16; Karnofsky ≥ 50% for older patients) **You may NOT be eligible if...** - Your leukemia cells do not express CD19 or CD22 (CD20 absence is acceptable) - Your general health is too poor - You have uncontrolled serious organ problems Talk to your doctor to see if this trial is right for you.